{"title":"连接素-4水平升高作为子痫前期的血清学标志物。","authors":"Hikari Yoshizawa, Haruki Nishizawa, Mayuko Ito, Akiko Ohwaki, Yoshiko Sakabe, Takao Sekiya, Takuma Fujii, Hiroki Kurahashi","doi":"10.20407/fmj.2022-027","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Nectin-4 is a cell adhesion molecule with vital functions at adherens and tight junctions. Cumulative evidence now indicates that the <i>NECTIN4</i> gene is overexpressed in a variety of cancers, and that the nectin-4 protein is both a disease marker and therapeutic target in a subset of these cancers. We previously demonstrated that <i>NECTIN4</i> is overexpressed in placenta during pre-eclamptic pregnancy, which is one of the most serious obstetric disorders.</p><p><strong>Methods: </strong>Nectin-4 protein levels were measured in maternal sera from pregnant women with pre-eclampsia and its related disorder, unexplained fetal growth retardation.</p><p><strong>Results: </strong>Maternal serum concentrations of nectin-4 were significantly elevated in pre-eclamptic women compared with those with an uncomplicated normotensive pregnancy. However, no increase was observed in pregnancies with unexplained fetal growth retardation. Serum nectin-4 levels were higher in cases with early-onset pre-eclampsia that generally showed more severe clinical symptoms, but levels were not correlated to other clinical indicators of disease severity.</p><p><strong>Conclusions: </strong>Nectin-4 is a potential new diagnostic and predictive biomarker for severe pre-eclampsia.</p>","PeriodicalId":33657,"journal":{"name":"Fujita Medical Journal","volume":"9 3","pages":"200-205"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405896/pdf/","citationCount":"0","resultStr":"{\"title\":\"Increased levels of nectin-4 as a serological marker for pre-eclampsia.\",\"authors\":\"Hikari Yoshizawa, Haruki Nishizawa, Mayuko Ito, Akiko Ohwaki, Yoshiko Sakabe, Takao Sekiya, Takuma Fujii, Hiroki Kurahashi\",\"doi\":\"10.20407/fmj.2022-027\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Nectin-4 is a cell adhesion molecule with vital functions at adherens and tight junctions. Cumulative evidence now indicates that the <i>NECTIN4</i> gene is overexpressed in a variety of cancers, and that the nectin-4 protein is both a disease marker and therapeutic target in a subset of these cancers. We previously demonstrated that <i>NECTIN4</i> is overexpressed in placenta during pre-eclamptic pregnancy, which is one of the most serious obstetric disorders.</p><p><strong>Methods: </strong>Nectin-4 protein levels were measured in maternal sera from pregnant women with pre-eclampsia and its related disorder, unexplained fetal growth retardation.</p><p><strong>Results: </strong>Maternal serum concentrations of nectin-4 were significantly elevated in pre-eclamptic women compared with those with an uncomplicated normotensive pregnancy. However, no increase was observed in pregnancies with unexplained fetal growth retardation. Serum nectin-4 levels were higher in cases with early-onset pre-eclampsia that generally showed more severe clinical symptoms, but levels were not correlated to other clinical indicators of disease severity.</p><p><strong>Conclusions: </strong>Nectin-4 is a potential new diagnostic and predictive biomarker for severe pre-eclampsia.</p>\",\"PeriodicalId\":33657,\"journal\":{\"name\":\"Fujita Medical Journal\",\"volume\":\"9 3\",\"pages\":\"200-205\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405896/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Fujita Medical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.20407/fmj.2022-027\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fujita Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20407/fmj.2022-027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Increased levels of nectin-4 as a serological marker for pre-eclampsia.
Objectives: Nectin-4 is a cell adhesion molecule with vital functions at adherens and tight junctions. Cumulative evidence now indicates that the NECTIN4 gene is overexpressed in a variety of cancers, and that the nectin-4 protein is both a disease marker and therapeutic target in a subset of these cancers. We previously demonstrated that NECTIN4 is overexpressed in placenta during pre-eclamptic pregnancy, which is one of the most serious obstetric disorders.
Methods: Nectin-4 protein levels were measured in maternal sera from pregnant women with pre-eclampsia and its related disorder, unexplained fetal growth retardation.
Results: Maternal serum concentrations of nectin-4 were significantly elevated in pre-eclamptic women compared with those with an uncomplicated normotensive pregnancy. However, no increase was observed in pregnancies with unexplained fetal growth retardation. Serum nectin-4 levels were higher in cases with early-onset pre-eclampsia that generally showed more severe clinical symptoms, but levels were not correlated to other clinical indicators of disease severity.
Conclusions: Nectin-4 is a potential new diagnostic and predictive biomarker for severe pre-eclampsia.